A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
A study for patients with Central Nervous System Lymphoma (PCNSL) or Primary Testicular Lymphoma (PTL) using study drug Nivolumab
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAQ8904
U.S. Govt. ID: NCT02857426
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). This study will see if treatment with nivolumab increases the chance you will have a positive response (complete or partial) in treating your primary central nervous system lymphoma (PCNSL) or primary testicular lymphoma (PTL). It will also see if nivolumab improves your chances of survival and at delaying the worsening of your PCNSL or PTL (called progression).
This study is closed
Fabio Iwamoto, MD
Do You Qualify?
Have you been diagnosed with Central Nervous System Lymphoma (PCNSL) or Primary Testicular Lymphoma (PTL)? Yes No
Are you able to do an MRI? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator